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variables, existing complications and treatment status) are used to estimate the
transition probabilities for different eventswithHbA1c acting as the key variable in
themodel. Patient behaviourwas also incorporated in the cost-effectivenessmodel
by updating HbA1c and other variables in time based on the patient’s behaviour.
Furthermore, the model is capable of performing probabilistic sensitivity analysis
allowing us to capture the effects of parameter uncertainty and report the likeli-
hood that interventions are cost-effective. RESULTS: A number of cost-effective
analyses were performed and the trade-offs between costs and QALYs are pre-
sented for different treatment/interventions. Screening strategies were also eval-
uated by comparing the cost savings and improvements in life expectancy.
CONCLUSIONS: The flexible individual patient level discrete event simulation
model developed enables cost-effectiveness evaluations of a number of treatments
and interventions for Type-1 diabetes. The model allows tracking the history of
each of the patients and this enables identification of different sub-groups for
targeted interventions.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes & Patient
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COMPARING MEDICATION ADHERENCE, PERSISTENCE AND DISCONTINUATION
RATES TO PREGABALIN AND DULOXETINE AMONG TYPE 2 DIABETIC PATIENTS
Oladapo AO, Adeyemi A, Barner JC
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To compare medication adherence, persistence and discontinuation
rates tomedications used to treat painful diabetic peripheral neuropathy (PDPN) in
type 2 diabetic patients.METHODS: A retrospective cohort analysis of Texas Med-
icaid prescription claims data of type 2 diabetic patients between 18 and 64 years
whowere on either pregabalin or duloxetine. Datawere extracted from June 2003 to
October 2009. Eligible patients must have been on oral antidiabetic (OAD) medica-
tions at least 6months prior to the index date and have continuous eligibility for at
least 12 months post-index. Cohorts were constructed through propensity scoring
while controlling for baseline differences in demographics and pre-index medica-
tion use. The outcome variables were medication possession ratio (MPR), persis-
tence and discontinuation rates. Sensitivity analyses were conducted for both per-
sistence and discontinuation rates. RESULTS: The two study cohorts included 652
pregabalin and 652 duloxetine patientswith an overallmean age of 51.97.9.Mean
MPR for duloxetine (85.6%  18.2%) was significantly higher compared to pregaba-
lin (68.6% 25.0%); t 14.03; p□ 0.0001. The proportion of adherent patients
(MPR80%) on duloxetine (72.1%) was higher compared to pregabalin (40.2%); X2
134.74; p□0.001. Mean persistence for duloxetine (222.9 days  130.5) was signifi-
cantly longer compared to pregabalin (165.1 days 128.3)when a 60-day gap period
was used; t7.98; p□0.0001. Results of sensitivity analysis using 30, 90 and 120 days
gap periodswere robust. Also, the proportion of patients on duloxetine (65.5%)who
discontinued their medication was lower compared to pregabalin (79.8%) when a
90-day gap period was used (X2 38.94; p□0.0001). Results of sensitivity analysis
using 60 and 120 day gaps were also robust. CONCLUSIONS: Type 2 diabetes pa-
tients on duloxetine had significantly higher medication adherence and persis-
tence with lower discontinuation rates compared to patients on pregabalin.
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THE ECONOMIC IMPACT OF INCREASING THE LEVEL OF DRUG ADHERENCE IN
DIABETIC PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
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Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, D.F, Mexico
OBJECTIVES: The lack of adherence to diabetic drugsmay reduce the effectiveness
of the treatment increasing the hospitalization rates and costs. The purpose of this
study is to estimate the economic savings derived from comparing different dia-
betic drug adherence scenarios at the Mexican Institute of Social Security (IMSS).
METHODS: For patients with non-complicated diabetes mellitus, 19 pharmacolog-
ical treatment patterns and their distribution were identified by a panel of experts
from primary medical units and general and specialized hospitals. The total pop-
ulation of diabetic patients at IMSS in the year 2010was obtained from the diabetes
census; the percentage of patients under pharmacological treatment came from
the institutional health survey of 2010. Four drug adherence scenarios derived from
institutional studies were considered. All-cause hospitalization rates among dia-
betes drug adherent and non-adherent patients were derived from the interna-
tional literature due to the lack of national estimations. The annual total costs
included the pharmacological and all-cause hospitalization estimates for each
treatment pattern. The exchange rate was $12.34 pesos per dollar. RESULTS: The
metformin-glibenclamide combination was the most prescribed pharmacological
treatment at the Institute (26.6%) followed by metformin-insulin NPH (11.8%) and
metformin (11.2%). The diabetic drug adherence baseline scenario was 16%; this
was compared with three scenarios of 17.2%, 27% and 54.2% respectively. The
annual total costs were 6.05 times greater in non-adherent compared with adher-
ent patients in the baseline scenario. The economic savings increases as the level
of compliance scales up. This can be attributed to the cost reductions compared to
non-adherent patients mainly due to hospitalization. In the year 2010, savings
varied fromUSD$1.48million toUSD$47.01million.CONCLUSIONS:Health policies
that aim to increase adherence to diabetic drugs among patients are needed at the
institution in order to avoid unnecessary costs mainly among non-adherent pa-
tients.
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OBJECTIVES: The aim of the current study was to determine the association be-
tweenmedicationnon-adherence andHbA1c levels among type 2 diabetes patients
currently using basal insulin analogues. METHODS: Data from the 2011 U.S. Na-
tional Health and Wellness Survey (NHWS) were used. The NHWS is a patient-
reported survey fielded to a demographically-representative sample of the adult US
population (N75,000). Analyses were restricted to those who reported a diagnosis
of type 2 diabetes, were currently using insulin glargine or insulin detemir, had
non-missing self-reported HbA1c values, and had non-missing medication adher-
ence data (assessed using the Morisky Medication Adherence Scale (MMAS)). The
association between medication non-adherence and HbA1c was examined using
multiple regressions controlling for sociodemographics, health behaviors, and
comorbidities. RESULTS: A total of 768 patients met the study inclusion criteria.
These patients weremostlymale (64.71%), had amean age of 61.39 (SD9.85), were
predominantly obese (72.92%), and reported a mean HbA1c level of 7.31%
(SD1.41%). A third of patients (33.20%) reported engaging in at least one non-
adherent behavior; the most common was being forgetful with their medication
(28.52%) followed by being careless with their medication (13.02%). Adjusting for
covariates, a higher non-adherence score was significantly associated with in-
creased HbA1c (b0.33, p.0001). When entering all non-adherent behaviors from
theMMAS separately into themodel being careless (b0.44, p.008) was the stron-
gest predictor of increased HbA1c levels. CONCLUSIONS: The results suggest that a
sizeable proportion of T2D patients using basal insulin analogues engage in some
form of non-adherent behavior, the most common being forgetfulness and care-
lessness with the administration of their medication. Even after adjusting for con-
founding variables, the presence of non-adherent behaviors (particularly careless-
ness) was associated with significantly higher levels of HbA1c. Improved
adherence of these patients may result in clinical benefits.
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OBJECTIVES: To provide an overview of subjective and objective measures used in
clinical trials to assess adherence or compliance to medical treatment in diabetes
mellitus, to identify trends in the measurement of adherence/compliance, stan-
dardization, and/or tool usage frequency.METHODS:The searchwas performed on
September 1, 2011 and was limited to articles written since 2000. The following
keywords and their descriptors inMedline viaOVIDwere used: patient compliance,
adherence, clinical trials, and diabetes mellitus. Once the abstracts had been re-
trieved, they were carefully reviewed and either selected or rejected, according a
ranking process. RESULTS: A total of 508 references were retrieved and 108 se-
lected. Forty-eight measures were identified: 36 to assess adherence, and 12 to
assess compliance. Among the adherence measures, 27 were subjective measures
such as patient-reported outcome (PRO) instruments and nine, objective. The
most-quoted subjectivemeasures usedwere theDiabetes Self-Management Profile
(DSMP) conventional or flexible regimen versions (four times); the Summary of
Diabetes Self-Care Activities (SDSCA) (four times); the five-itemMedication Adher-
ence Report Scale (MARS-5) (two times); theMoriskyMedication-Taking Adherence
Scale (MMAS) (two times); and the Brief Medication Questionnaire (BMQ) (two
times). Themost-quoted objectivesmeasures to assess adherencewere the refill of
repeat prescriptions (cited six times) and pill cap monitoring systems (five times).
As for the assessment of compliance, only two were subjective measures and ten
were objective. The PROmeasures retrieved were the Chronic Disease Compliance
Instrument and a Medication Compliance Scale. The most frequently used objec-
tivemeasure was the evaluation of return of study drugs. CONCLUSIONS:Diabetes
is a challenging disease to manage successfully and the associated costs of non-
adherence are high. This review shows a lack of standardization/consistency in the
measurement of adherence/compliance in diabetes. More research is needed on
what are the “best” tools to use tomeasure adherence-related behavior in diabetes.
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OBJECTIVES: The impact of adherence to hypoglycemic agents on the medical/
pharmacy costs of diabetes patients has been examined frequently in the litera-
ture, but the analogous impact on disability costs is not well-documented. This
study assesses the relationships between medication adherence and short-term
disability costs in a large manufacturing company. METHODS: A retrospective
analysis of pharmacy claims was conducted to identify individuals within a large
manufacturing company who were continuously eligible for a three-year time
frame (between 2001 and 2007) and who received a prescription for an oral hypo-
glycemic during that time; in those cases where an individual’s eligibility spanned
a longer time period, the most recent three-year span was chosen. Individuals on
insulin were excluded from the study population. The resulting sample included
both treatment-naïve and treatment-experienced patients, reflective of real-world
employer experience. Medical, pharmacy, and short-term disability costs were cal-
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